245 related articles for article (PubMed ID: 26953202)
1. Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia.
Britt NS; Patel N; Horvat RT; Steed ME
Antimicrob Agents Chemother; 2016 May; 60(5):3070-5. PubMed ID: 26953202
[TBL] [Abstract][Full Text] [Related]
2. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
[TBL] [Abstract][Full Text] [Related]
3. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
4. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
Gawronski KM; Goff DA; Brown J; Khadem TM; Bauer KA
Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
[TBL] [Abstract][Full Text] [Related]
5. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
[TBL] [Abstract][Full Text] [Related]
6. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
BMC Infect Dis; 2017 Aug; 17(1):534. PubMed ID: 28764660
[TBL] [Abstract][Full Text] [Related]
7. More accurate measurement of vancomycin minimum inhibitory concentration indicates poor outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
Shoji H; Maeda M; Shirakura T; Takuma T; Ugajin K; Fukuchi K; Ishino K; Niki Y
Int J Antimicrob Agents; 2015 Nov; 46(5):532-7. PubMed ID: 26364848
[TBL] [Abstract][Full Text] [Related]
8. Impact of Vancomycin MIC on Clinical Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin at an Institution with Suppressed MIC Reporting.
Adani S; Bhowmick T; Weinstein MP; Narayanan N
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378704
[TBL] [Abstract][Full Text] [Related]
9. Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study.
Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Lodise TP
Diagn Microbiol Infect Dis; 2017 Jul; 88(3):259-263. PubMed ID: 28449844
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin AUC24 /MIC Ratio in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia.
Ji M; Kim HK; Kim SK; Lee W; Sung H; Chun S; Kim MN; Min WK
J Clin Lab Anal; 2016 Sep; 30(5):485-9. PubMed ID: 26499918
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.
Brown J; Brown K; Forrest A
Antimicrob Agents Chemother; 2012 Feb; 56(2):634-8. PubMed ID: 22123681
[TBL] [Abstract][Full Text] [Related]
12. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Ghosh N; Chavada R; Maley M; van Hal SJ
Clin Microbiol Infect; 2014 Dec; 20(12):O1098-105. PubMed ID: 24890030
[TBL] [Abstract][Full Text] [Related]
13. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
[TBL] [Abstract][Full Text] [Related]
14. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
Kullar R; Davis SL; Levine DP; Rybak MJ
Clin Infect Dis; 2011 Apr; 52(8):975-81. PubMed ID: 21460309
[TBL] [Abstract][Full Text] [Related]
15. Impact of Vancomycin MIC on Treatment Outcomes in Invasive Staphylococcus aureus Infections.
Song KH; Kim M; Kim CJ; Cho JE; Choi YJ; Park JS; Ahn S; Jang HC; Park KH; Jung SI; Yoon N; Kim DM; Hwang JH; Lee CS; Lee JH; Kwak YG; Kim ES; Park SY; Park Y; Lee KS; Lee YS; Kim HB
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956430
[TBL] [Abstract][Full Text] [Related]
16. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.
Casapao AM; Lodise TP; Davis SL; Claeys KC; Kullar R; Levine DP; Rybak MJ
Antimicrob Agents Chemother; 2015; 59(6):2978-85. PubMed ID: 25753631
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
[TBL] [Abstract][Full Text] [Related]
19. Impact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children.
Yoo R; So H; Seo E; Kim M; Lee J
PLoS One; 2021; 16(4):e0247714. PubMed ID: 33793589
[TBL] [Abstract][Full Text] [Related]
20. Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.
Britt NS; Patel N; Shireman TI; El Atrouni WI; Horvat RT; Steed ME
J Antimicrob Chemother; 2017 Feb; 72(2):535-542. PubMed ID: 27999028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
